Skip to content

A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)

Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003144
Enrollment
Unknown
Registered
2020-03-22
Start date
2020-03-13
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Sponsors

Guangzhou Eighth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have been diagnosed as COVID-19 according to The Diagnosis and Treatment Plan for 2019-nCoV(The Fifth Trial Edition); 2. aged between 18 to 80 years old, male or female; 3. the subjects participating the clinical trial are voluntary and sign the informed consent, thoroughly informed the purpose, method, possible reaction.

Exclusion criteria

Exclusion criteria: 1. Patients who are difficult to be administered orally or by nasal feeding, those who are allergic to the test drug and those who are intolerant to the drug; 2. The compliance of medication cannot be guaranteed during the treatment 3. Patients with severe primary respiratory diseases, or pneumonia caused by other pathogen. 4. Patients with serious diseases, malignant tumors or mental diseases; 5. Pregnant women, urine pregnancy test positive; 6. Participated in other drug trials in the past month; 7. The investigator judged that the patient was not suitable for the study.

Design outcomes

Primary

MeasureTime frame
nucleic acid of nCoV-19;syndrome;

Secondary

MeasureTime frame
lung CT;cardiac enzymes;liver and kidney function;blood count;

Countries

China

Contacts

Public ContactLuping Lin

Guangzhou Eighth People's Hospital

13533550083@163.com+86 13533550083

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026